Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 393-396

  Jahan, Thierry ^a   Gu, Lin ^b   Kratzke, Robert ^c   Dudek, Arkadiusz ^c   Otterson, Gregory A ^d   Wang, Xiaofei ^b   Green, Mark ^e   Vokes, Everett E ^f   Kindler, Hedy Lee ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALGB Statistical Center   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Roper St Francis Healthcare   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clinical trial phase II; Mesothelioma; Molecular targeted therapy; PDGFB; Vatalanib; VEGF Receptor

Indexed keywords

BIOLOGICAL MARKER; MESOTHELIN; PLATELET DERIVED GROWTH FACTOR; THROMBOSPONDIN 1; VASCULOTROPIN; VATALANIB;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD LEVEL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; MALE; MESOTHELIOMA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SERUM; SIDE EFFECT; SYNCOPE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PHTHALAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PYRIDINES; SURVIVAL ANALYSIS; THROMBOSPONDIN 1; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860525842     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.11.014     Document Type: Article

References (24)

1. Campbell N.P., Kindler H.L. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 2011, 32(1):102-110.
2. Tsao A.S., Wistuba I., Roth J.A., Kindler H.L. Malignant pleural mesothelioma. J Clin Oncol 2009, 27(12):2081-2090.
3. Dowell J., Kindler H.L. Anti-angiogenic therapies for mesothelioma. Hematol Oncol Clin North Am 2005, 19(6):1137-1146.
4. Linder C., Linder S., Munck-Wikland E., Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998, 18(3B):2063-2068.
5. Ohta Y., Shridhar V., Bright R.K., Kalemkerian G.P., Du W., Carbone M., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999, 81(1):54-61.
6. Strizzi L., Catalano A., Vianale G., Orecchia S., Casalani A., Tassi G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468-475.
7. Li Q., Yano S., Ogino H., Wang W., Uehara H., Nishioka Y., et al. The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab and pemetrexed against orthotopically implanted human mesothelioma cells in SCID mice. Clin Cancer Res 2007, 13:5918-5925.
8. Merritt R.E., Yamada R.E., Wasif N., Crystal R.G., Korst R.J., et al. Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma. Ann Thorac Surg 2004, 78:1042-1051.
9. Pogrebniak H., Lubesky I., Pass H. Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapeutics. Surg Oncol 1993, 2:235-240.
10. Langerhak A., De Laat P., Van Der Linden-Van Beurden C.A., Delahaye M., Van Der Kwast T.H., Hoogesten H.C., et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 1996, 178:151-160.
11. Klominek J., Baskin B., Hauzenberg D. Platelet derived growth factor (PDGF) BB acts as a chemo attractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha 3 beta 1 interaction. Clin Exp Metastasis 1998, 16:529-539.
12. Bjorkvist A., Tammilehto L., Antila S., Mattson K., Knuutila S., et al. Recurrent DNA Copy number changes in 1q, 4q, 6q, 13q, 14q, and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 1997, 75:523-527.
13. Lee W., Testa J. Somatic genetic alterations in human malignant mesothelioma. Int J Oncol 1999, 14:181-188.
14. Pech M., Gazit A., Arnstein P., Aaronson S.A. Generation of fibrosarcomas in vivo by a retrovirus that expresses the normal B chain of platelet-derived growth factor and mimics the alternative splice pattern of the v-sis oncogene. Proc Natl Acad Sci USA 1989, 86:2693-2697.
15. Forsberg K., Valyi-Nagy I., Heldin C., Herlyn M., Westermark B. Platelet derived growth factor (PDGF) in oncogenesis development of a vascular connective tissue stroma in xeno transplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 1993, 90:393-397.
16. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178-2189.
17. Hecht J., Trarbach T., Hainsworth J.D., Major P., Jager E., Wolff R.A., et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011, (4). [epub ahead of print].
18. Van Cutsem E., Bajetta E., Valle J., Kohne C.H., Hecht J.R., Moore M., et al. Randomized, placebo-controlled phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously-treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011, (4). [epub ahead of print].
19. Byrne M.J., Nowak A.K. Modif.ied RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15(2):257-260.
20. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., Vogelsang N.J., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723-731.
21. Kaplan E., Meier P. Nonparametric estimations of incomplete observations. J Am Stat Assoc 1958, 53:457-481.
22. Francart J., Vaes E., Henrard S., Legrand C., Baas P., Gaafar R., et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 2009, 45(13):2304-2311.
23. Thomas A.L., Morgan B., Horsfield M.A., Higginson A., Kay A., Lee L., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005, 23(18):4162-4171.
24. Greillier L., Marco S., Barlesi F. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies. Anticancer Drugs 2011, 22(3):199-205.